Advertisement

Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials

      Background

      Sodium-glucose cotransporter 2 inhibitors (SGLT2is) reduce hospitalizations and death from heart failure (HF), but their effect on arrhythmia expression has been poorly investigated.

      Objective

      The purpose of this study was to evaluate the association of SGLT2is with arrhythmias in patients with type 2 diabetes mellitus (T2DM) or HF.

      Methods

      We searched PubMed and ClinicalTrials.gov. Two independent investigators identified randomized double-blind trials that compared SGLT2is with placebo or active control for adults with T2DM or HF. Primary outcomes were incident atrial arrhythmias, ventricular arrhythmias (VAs), and sudden cardiac death (SCD).

      Results

      We included 34 randomized (25 placebo-controlled and 9 active-controlled) trials with 63,166 patients (35,883 SGLT2is vs 27,273 control: mean age 53–67 years; 63% male). Medications included canagliflozin, dapagliflozin, empagliflozin, or ertugliflozin. Except for 1 study of HF, all patients had T2DM. Follow-up ranged from 24 weeks to 5.7 years. The cumulative incidence of events was low: 3.6, 1.4, and 2.5 per 1000 patient-years for atrial arrhythmias, VAs and SCD, respectively. SGLT2i therapy was associated with a significant reduction in the risk of incident atrial arrhythmias (odds ratio 0.81; 95% confidence interval 0.69–0.95; P = .008) and the “SCD” component of the SCD outcome (odds ratio 0.72; 95% confidence interval 0.54–0.97; P = .03) compared with control. There was no significant difference in incident VA or the “cardiac arrest” SCD component between groups.

      Conclusion

      SGLT2is are associated with significantly reduced risks of incident atrial arrhythmias and SCD in patients with T2DM. Prospective trials are warranted to confirm the antiarrhythmic effect of SGLT2is and whether this is a class or drug-specific effect.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Heart Rhythm
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bell D.S.H.
        • Goncalves E.
        Atrial fibrillation and type 2 diabetes: prevalence, etiology, pathophysiology and effect of anti-diabetic therapies.
        Diabetes Obes Metab. 2019; 21: 210-217
        • Lynge T.H.
        • Svane J.
        • Pedersen-Bjergaard U.
        • et al.
        Sudden cardiac death among persons with diabetes aged 1-49 years: a 10-year nationwide study of 14 294 deaths in Denmark.
        Eur Heart J. 2020; 41: 2699-2706
        • McMurray J.J.V.
        • Solomon S.D.
        • Inzucchi S.E.
        • et al.
        Dapagliflozin in patients with heart failure and reduced ejection fraction.
        N Engl J Med. 2019; 381: 1995-2008
        • Neal B.
        • Perkovic V.
        • Mahaffey K.W.
        • et al.
        Canagliflozin and cardiovascular and renal events in type 2 diabetes.
        N Engl J Med. 2017; 377: 644-657
        • Perkovic V.
        • Jardine M.J.
        • Neal B.
        • et al.
        Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.
        N Engl J Med. 2019; 380: 2295-2306
        • Wiviott S.D.
        • Raz I.
        • Bonaca M.P.
        • et al.
        Dapagliflozin and cardiovascular outcomes in type 2 diabetes.
        N Engl J Med. 2019; 380: 347-357
        • Zinman B.
        • Wanner C.
        • Lachin J.M.
        • et al.
        Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.
        N Engl J Med. 2015; 373: 2117-2128
        • Packer M.
        • Anker S.D.
        • Butler J.
        • et al.
        Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action.
        JAMA Cardiol. 2017; 2: 1025-1029
        • Verma S.
        • McMurray J.J.V.
        SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review.
        Diabetologia. 2018; 61: 2108-2117
        • Cherney D.Z.
        • Odutayo A.
        • Aronson R.
        • et al.
        Sodium Glucose Cotransporter-2 Inhibition and Cardiorenal Protection: JACC Review Topic of the Week.
        J Am Coll Cardiol. 2019; 74: 2511-2524
      1. Higgins J.P.T. Thomas J. Chandler J. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2011 (Accessed April 11, 2021)
        • Bailey C.J.
        • Gross J.L.
        • Pieters A.
        • et al.
        Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.
        Lancet. 2010; 375: 2223-2233
        • Lavalle-Gonzalez F.J.
        • Januszewicz A.
        • Davidson J.
        • et al.
        Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
        Diabetologia. 2013; 56: 2582-2592
        • Schernthaner G.
        • Gross J.L.
        • Rosenstock J.
        • et al.
        Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.
        Diabetes Care. 2013; 36: 2508-2515
        • Cefalu W.T.
        • Leiter L.A.
        • Yoon K.H.
        • et al.
        Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.
        Lancet. 2013; 382: 941-950
        • Cefalu W.T.
        • Leiter L.A.
        • de Bruin T.W.
        • et al.
        Dapagliflozin’s effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension.
        Diabetes Care. 2015; 38: 1218-1227
        • Frias J.P.
        • Guja C.
        • Hardy E.
        • et al.
        Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
        Lancet Diabetes Endocrinol. 2016; 4: 1004-1016
        • Verma S.
        • Mazer C.D.
        • Yan A.T.
        • et al.
        Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial.
        Circulation. 2019; 140: 1693-1702
        • Rosenstock J.
        • Jelaska A.
        • Zeller C.
        • et al.
        Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.
        Diabetes Obes Metab. 2015; 17: 936-948
        • Roden M.
        • Merker L.
        • Christiansen A.V.
        • et al.
        Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naive patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial.
        Cardiovasc Diabetol. 2015; 14: 154
        • Ridderstrale M.
        • Rosenstock J.
        • Andersen K.R.
        • et al.
        Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial.
        Diabetes Obes Metab. 2018; 20: 2768-2777
        • Haring H.U.
        • Merker L.
        • Seewaldt-Becker E.
        • et al.
        Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
        Diabetes Care. 2013; 36: 3396-3404
        • Kovacs C.S.
        • Seshiah V.
        • Swallow R.
        • et al.
        Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
        Diabetes Obes Metab. 2014; 16: 147-158
        • Barnett A.H.
        • Mithal A.
        • Manassie J.
        • et al.
        Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
        Lancet Diabetes Endocrinol. 2014; 2: 369-384
        • Ferrannini E.
        • Ramos S.J.
        • Salsali A.
        • et al.
        Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.
        Diabetes Care. 2010; 33: 2217-2224
        • Januzzi Jr., J.L.
        • Butler J.
        • Jarolim P.
        • et al.
        Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes.
        J Am Coll Cardiol. 2017; 70: 704-712
        • Leiter L.A.
        • Cefalu W.T.
        • de Bruin T.W.
        • et al.
        Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension.
        J Am Geriatr Soc. 2014; 62: 1252-1262
        • Mathieu C.
        • Ranetti A.E.
        • Li D.
        • et al.
        Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes.
        Diabetes Care. 2015; 38: 2009-2017
        • Muller-Wieland D.
        • Kellerer M.
        • Cypryk K.
        • et al.
        Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes.
        Diabetes Obes Metab. 2018; 20: 2598-2607
        • Nauck M.A.
        • Del Prato S.
        • Meier J.J.
        • et al.
        Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.
        Diabetes Care. 2011; 34: 2015-2022
        • Rosenstock J.
        • Aggarwal N.
        • Polidori D.
        • et al.
        Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.
        Diabetes Care. 2012; 35: 1232-1238
        • Rosenstock J.
        • Chuck L.
        • González-Ortiz M.
        • et al.
        Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-naïve type 2 diabetes.
        Diabetes Care. 2016; 39: 353-362
        • Softeland E.
        • Meier J.J.
        • Vangen B.
        • et al.
        Empagliflozin as add-on therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin: a 24-week randomized, double-blind, parallel-group trial.
        Diabetes Care. 2017; 40: 201-209
        • Pratley R.E.
        • Eldor R.
        • Raji A.
        • et al.
        Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: the VERTIS FACTORIAL randomized trial.
        Diabetes Obes Metab. 2018; 20: 1111-1120
        • Rosenstock J.
        • Frias J.
        • Pall D.
        • et al.
        Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).
        Diabetes Obes Metab. 2018; 20: 520-529
        • Grunberger G.
        • Camp S.
        • Johnson J.
        • et al.
        Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: the VERTIS RENAL randomized study.
        Diabetes Ther. 2018; 9: 49-66
        • Hollander P.
        • Liu J.
        • Hill J.
        • et al.
        Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: the VERTIS SU randomized study.
        Diabetes Ther. 2018; 9: 193-207
        • Wilding J.P.
        • Woo V.
        • Soler N.G.
        • et al.
        Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.
        Ann Intern Med. 2012; 156: 405-415
        • Usman M.S.
        • Siddiqi T.J.
        • Memon M.M.
        • et al.
        Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis.
        Eur J Prev Cardiol. 2018; 25: 495-502
        • Matthews V.B.
        • Elliot R.H.
        • Rudnicka C.
        • et al.
        Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2.
        J Hypertens. 2017; 35: 2059-2068
        • Chen H.Y.
        • Huang J.Y.
        • Siao W.Z.
        • et al.
        The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study.
        Cardiovasc Diabetol. 2020; 19: 73
        • Zelniker T.A.
        • Bonaca M.P.
        • Furtado R.H.M.
        • et al.
        Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial.
        Circulation. 2020; 141: 1227-1234